aTyr Pharma develops medicines based on novel immunological pathways. Its lead candidate, efzofitimod, is in Phase III trials for pulmonary sarcoidosis and ILDs like chronic hypersensitivity pneumonitis. Another candidate, ATYR0101, is in preclinical development for fibrosis treatment. The company also has ATYR0750 in development for liver disorders. aTyr Pharma collaborated with Kyorin Pharmaceutical Co., Ltd. on efzofitimods development and commercialization in Japan.
| Indicator | Value |
|---|---|
| PER | 15.4 |
| EV/EBITDA | - |
| Price/Free Cash Flow' | 36.6 |
| ROIC | -% |
| Net Debt/EBITDA | - |